Uncomplicated vaginal delivery in two consecutive pregnancies carried to term in a woman with osteogenesis imperfecta type I and bisphosphonate treatment before conception

被引：9
作者：
Chen, Chih-Ping [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Lin, Shuan-Pei [3 ,8 ,9 ]
Su, Yi-Ning [10 ]
Huang, Jian-Pei [1 ]
Chern, Schu-Rern [3 ]
Su, Jun-Wei [1 ,11 ]
Wang, Wayseen [3 ,12 ]
机构：
[1] Mackay Mem Hosp, Dept Obstet & Gynecol, Taipei, Taiwan
[2] Mackay Med Coll, Dept Med, New Taipei City, Taiwan
[3] Mackay Mem Hosp, Dept Med Res, Taipei, Taiwan
[4] Asia Univ, Dept Biotechnol, Taichung, Taiwan
[5] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung, Taiwan
[6] Natl Yang Ming Univ, Inst Clin & Community Hlth Nursing, Taipei 112, Taiwan
[7] Natl Yang Ming Univ, Dept Obstet & Gynecol, Sch Med, Taipei 112, Taiwan
[8] Mackay Mem Hosp, Dept Pediat, Taipei, Taiwan
[9] Mackay Med Nursing & Management Coll, Taipei, Taiwan
[10] Natl Taiwan Univ Hosp, Dept Med Genet, Taipei, Taiwan
[11] China Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan
[12] Tatung Univ, Dept Bioengn, Taipei 104, Taiwan
来源：
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY | 2012年 / 51卷 / 02期
关键词：
PAMIDRONATE TREATMENT; BONE-RESORPTION; ALENDRONATE; INHIBITION; COLLAGEN;
D O I：
10.1016/j.tjog.2012.04.029
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
[No abstract available]
引用
收藏
页码：305 / 307
页数：3
相关论文
共 19 条
  • [1] CARLSON JW, 1993, J REPROD MED, V38, P228
  • [2] Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: A report of four cases
    Chan, Brendan
    Zacharin, Margaret
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06) : 2017 - 2020
  • [3] Prospective comparative case study of uterine collagen in a woman with osteogenesis imperfecta type 1 who had previously ruptured her uterus
    Christodoulou, S.
    Freemont, A. J.
    McVey, R.
    Vause, S.
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2007, 27 (07) : 738 - 739
  • [4] Osteogenesis imperfecta: Mode of delivery and neonatal outcome
    Cubert, R
    Cheng, EY
    Mack, S
    Pepin, MG
    Byers, PH
    [J]. OBSTETRICS AND GYNECOLOGY, 2001, 97 (01) : 66 - 69
  • [5] Collagen content and growth factor immunoexpression in uterine lower segment of type IA osteogenesis imperfecta: Relationship with recurrent uterine rupture in pregnancy
    Di Lieto, A
    Pollio, F
    De Falco, M
    Iannotti, F
    Mascolo, M
    Somma, P
    Staibano, S
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (02) : 594 - 600
  • [6] Does Treatment With Bisphosphonates Endanger the Human Pregnancy?
    Djokanovic, Nada
    Klieger-Grossmann, Chagit
    Koren, Gideon
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2008, 30 (12) : 1146 - 1148
  • [7] Alendronate mechanism of action:: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
    Fisher, JE
    Rogers, MJ
    Halasy, JM
    Luckman, SP
    Hughes, DE
    Masarachia, PJ
    Wesolowski, G
    Russell, RGG
    Rodan, GA
    Reszka, AA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) : 133 - 138
  • [8] Bisphosphonates: Mechanisms of action
    Fleisch, H
    [J]. ENDOCRINE REVIEWS, 1998, 19 (01) : 80 - 100
  • [9] GRAEPEL P, 1992, ARZNEIMITTEL-FORSCH, V42-1, P654
  • [10] Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis
    Halasy-Nagy, JM
    Rodan, GA
    Reszka, AA
    [J]. BONE, 2001, 29 (06) : 553 - 559
12